Nifty Healthcare Index News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Nifty Healthcare Index from all sources in a single place.

Load latest

Laurus Labs Ltd.

11 Apr 2025

605.85

7.37%

Laurus Labs surges 8%, stock records sharpest intraday gain since Jan 30

Business Standard

The pipeline is expected to be robust, and the company expects to do well in the human health and animal health CDMO divisions in Q4FY25E and in FY26E, according to analysts.

Laurus Labs Ltd. has gained 27.78% in the last 6 Months

Biocon Ltd.

11 Apr 2025

316.55

3.35%

Biocon shares jump 5.5% as USFDA clears biosimilar Cancer drug JOBEVNE

livemint

Biocon's share price rose 5.5% after USFDA approved JOBEVNE, a biosimilar cancer drug. This marks the company's seventh USFDA-approved biosimilar and enhances its oncology portfolio, increasing investor confidence and market optimism.

Biocon Ltd. is trading below all available SMAs

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

Business Standard | 11 Apr 2025 1 more

Aurobindo Pharma Ltd.

11 Apr 2025

1082.45

2.31%

Company Update

Aurobindo Pharma Ltd - 524804 - Completion Of US FDA Inspection At Raleigh Plant, North Carolina, …

BSE India

Intimation of completion of US FDA inspection at Raleigh Plant, North Carolina, owned by Aurolife Pharma LLC, a wholly owned stepdown subsidiary of the Company.

pdf

Cipla Ltd.

11 Apr 2025

1463.05

3.35%

Cipla gets USFDA nod to market generic version of cancer drug Abraxane

Business Standard

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.

Number of FII/FPI investors decreased from 1132 to 1077 in Dec 2024 qtr

Cipla gets USFDA nod for generic cancer drug

Business Line | 11 Apr 2025 1 more

Aurobindo Pharma Ltd.

11 Apr 2025

1082.45

2.31%

Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug

Business Standard

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the cells that break down bone

Promoters unpledged 2.56% of shares in last quarter. Total pledge stands at 17.83% of promoter holdings

Cipla Ltd.

11 Apr 2025

1463.05

3.35%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure …

BSE India

Company has received final approval from USFDA for ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (''Protein-bound Paclitaxel'') on 10th April, 2025

pdf

Laurus Labs Ltd.

10 Apr 2025

605.85

7.37%

Company Update

Laurus Labs Ltd - 540222 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Please see annexed enclosure.

pdf

Laurus Labs Ltd.

10 Apr 2025

605.85

7.37%

Company Update

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Please see annexed enclosure.

pdf

Biocon Ltd.

10 Apr 2025

316.55

3.35%

Company Update

Biocon Ltd - 532523 - Notification To Stock Exchanges

BSE India

Notification to Stock Exchanges

pdf

Laurus Labs Ltd.

10 Apr 2025

605.85

7.37%

Board Meeting

Laurus Labs Ltd - 540222 - Board Meeting Intimation for Consideration Of Audited Financial Results For …

BSE India

Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/04/2025 ,inter alia, to consider and approve the audited financial results of the Company for the quarter and year ended March 31, 2025 and payment of 2nd Interim Dividend for FY 2024-25 and fixation of record date for determining the eligibility of shareholders, if approved.

pdf

Nifty Healthcare Index PB	5.7
Nifty Healthcare Index PE	36.7
Nifty Healthcare Index DIV	0.6
Nifty Healthcare Index EPS	363.6